Meditor Group Ltd buys 1, sells

Meditor Group SA recently filed its 13F report for the second quarter of 2022, which ended on 2022-06-30.

The 13F report details the stocks that were in a guru’s stock portfolio at the end of the quarter, although investors should note that these filings are limited in scope, containing only an overview of long stock positions. listed in the United States and American certificates of deposit at the end of the quarter. They are not required to include international holdings, short positions or other types of investments. Yet even this limited repository can provide valuable information.

16 BY CITY ROAD HAMILTON, D0 HM08

According to the latest 13F report, the guru’s stock portfolio contained 4 stocks valued at a total of $202.00 million. The main stocks were EXEL (79.48%), ESPR (14.05%) and INDA (3.33%).

According to data from GuruFocus, these were Meditor Group Ltd’s top five trades in the quarter.

Exelixis Inc.

Meditor Group Ltd reduced its investment in NAS:EXEL by 1,264,000 shares. The transaction had an impact of 11.95% on the equity portfolio. During the quarter, the stock traded at an average price of $20.64.

On 7/18/2022, Exelixis Inc traded at a price of $21.57 per share and a market capitalization of $6.92 billion. The stock has returned 28.39% over the past year.

GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 5 out of 10.

In terms of valuation, Exelixis Inc has a price/earnings ratio of 23.45, a price/book ratio of 3.00, an EV/EBITDA ratio of 13.87 and a price/sales ratio of 4.58.

The GF price-to-value ratio is 0.68, giving the stock a GF value rank of 10.

Esperion Therapeutic Inc

During the quarter, Meditor Group Ltd purchased 1,650,000 shares of NAS:ESPR for a total holding of 4,468,835. The transaction had a 3.73% impact on the equity portfolio. During the quarter, the stock traded at an average price of $7.9.

On 7/18/2022, Esperion Therapeutics Inc traded at a price of $6.5 per share and a market capitalization of $409.54 million. The stock has returned -62.75% over the past year.

GuruFocus gives the company a financial strength rating of 2 out of 10 and a profitability rating of 1 out of 10.

In terms of valuation, Esperion Therapeutics Inc has an EV to Ebitda ratio of -2.49 and a price-to-sales ratio of 2.32.

The GF price/value ratio is 0.64, giving the stock a GF value rank of 8.

iShares MSCI India ETF

Meditor Group Ltd reduced its investment in BATS:INDA by 148,800 shares. The transaction had an impact of 2.49% on the equity portfolio. During the quarter, the stock traded at an average price of $46.02.

On 7/18/2022, iShares MSCI India ETF traded at a price of $40 per share and a market capitalization of $4.02 billion. The stock has posted a return of -3.80% over the past year.

The data is insufficient to calculate the financial strength and profitability of the stock.

In terms of valuation, iShares MSCI India ETF has a price-to-earnings ratio of 20.48 and a price-to-book ratio of 3.23.

WisdomTree India Income Fund

Meditor Group Ltd reduced its investment in ARCA:EPI by 186,200 shares. The transaction had an impact of 2.39% on the equity portfolio. During the quarter, the stock traded at an average price of $37.19.

On 7/18/2022, WisdomTree India Earnings Fund traded at a price of $29.98 per share and a market capitalization of $659.56 million. The stock has returned 0.77% over the past year.

The data is insufficient to calculate the financial strength and profitability of the stock.

In terms of valuation, WisdomTree India Earnings Fund has a price-to-earnings ratio of 10.76 and a price-to-book ratio of 1.72.

Alkermes PLC

The guru sold his 603,790 share investment in NAS:ALKS. Previously, the stock had a weighting of 3.35% in the equity portfolio. The shares traded at an average price of $20.46 during the quarter.

On 7/18/2022, Alkermes PLC traded at a price of $29.38 per share and a market capitalization of $4.82 billion. The stock has returned 23.91% over the past year.

GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 3 out of 10.

In terms of valuation, Alkermes PLC has a price to book ratio of 4.44, an EV to EBITDA ratio of 212.54 and a price to sales ratio of 3.98.

The GF price/value ratio is 1.36, giving the stock a GF value rank of 1.

Please note that figures and facts quoted are at the time of writing this article and may not reflect the latest business data or company announcements.

You want to give your opinion on this article ? Do you have questions or concerns? Contact us here or email us at [email protected]!

This article is general in nature and does not represent the views of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendation. It has been written without taking into account your personal situation or financial goals. Our goal is to bring you data-driven fundamental analysis. The information on this site is in no way guaranteed to be complete, accurate or in any other way.